Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
Active, not recruiting · NCT06555796 · Registry updated 2026-09-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 1 | 2026-09-04 | NCT06555796 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Amgen | 180 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cabrini Hospital | Malvern | Australia | 12 |
| Chris Obrien Lifehouse | Camperdown | Australia | 17 |
| Fred Hutchinson Cancer Center | Seattle | United States | 250 |
| Levine Cancer Institute | Charlotte | United States | 110 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Oregon Health and Science University | Portland | United States | 382 |
| Peter MacCallum Cancer Centre | Melbourne | Australia | 149 |
| Thomas Jefferson University | Philadelphia | United States | 165 |
| University of Minnesota Medical Center Fairview | Minneapolis | United States | 5 |
| University of North Carolina at Chapel Hill | Chapel Hill | United States | 129 |
| University of Texas Southwestern Medical Center | Dallas | United States | 249 |